附件32.1

首席执行官和首席财务官的证明

根据《18 U.S.C.第 1350 》执行

根据18 U.S.C.第1350节,

根据采用的方法，

2002年Sarbanes-Oxley法案第906条的规定：

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Neal Walker, Interim President and Chief Executive Officer of Aclaris Therapeutics, Inc. (the “Company”), and Kevin Balthaser, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.	The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2024, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.	本季度报告中包含的信息在财务状况和经营成果方面，所有重要方面均得到了公正的呈现。

据此证明, the undersigned have set their hands hereto as of the 6^th 2024年11月的日子。


/s/ Neal Walker		Kevin Balthaser
Neal Walker		Kevin Balthaser
临时总裁兼首席执行官 (首席执行官)		首席财务官（信安金融主要财务官和会计主管）

*	本证书附带相关的10-Q表格，未被视为已提交给证券交易委员会，并且不应被引用到Aclaris Therapeutics, Inc.根据1933年修正案的《证券法》或《交易法案》下的任何申报，无论是在10-Q表格的日期之前还是之后制定（不考虑这些申报中可能包含的任何一般引用语言）。